welcome to DuchenneXchange

- a positively charged Duchenne muscular dystrophy community.
  • join today!

Sarepta shoots higher as sales of $300,000-a-year drug exceed expectations

Sarepta announced second-quarter revenue of $35 million, easily beating the average analyst forecast of $22.5 million, according to a FactSet survey. The company brought in nearly as much in sales during the second quarter as it did in the previous six fiscal years, when it recorded $36 million in revenue amid a nearly decade-long effort to get FDA approval for eteplirsen, the first approved treatment for DMD. Sarepta also increased its forecast for full-year revenue, to a range of $125 million to $130 million from previous guidance of more than $95 million.

Sarepta Shoots Higher As Sales Of $300,000-a-year Drug Exceed Expectations